Placebo + Seralutinib
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension Associated With Interstitial Lung Disease
Conditions
Pulmonary Hypertension Associated With Interstitial Lung Disease
Trial Timeline
Feb 1, 2026 → Dec 1, 2028
NCT ID
NCT07181382About Placebo + Seralutinib
Placebo + Seralutinib is a phase 3 stage product being developed by Gossamer Bio for Pulmonary Hypertension Associated With Interstitial Lung Disease. The current trial status is active. This product is registered under clinical trial identifier NCT07181382. Target conditions include Pulmonary Hypertension Associated With Interstitial Lung Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07181382 | Phase 3 | Active |
| NCT05934526 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension Associated With Interstitial Lung Disease